AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

CHMP positive opinion, supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, will now be referred to the European Commission for final approval[1-5] In Phase 3 trials, upadacitinib improved s... Biopharmaceuticals, Regulatory AbbVie, RINVOQ, upadacitinib, JAK inhibitor, rheumatoid arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news